Madison, WI-based radiopharmaceutical therapy developer Archeus Technologies has appointed a new slate of executives to lead the company as it enters its next stage of clinical growth.
Reinier Hernandez, PhD, has been appointed chief technology officer and Zachary Morris, MD, PhD, has been named chief medical officer, the company said. In addition, Norman LaFrance, MD, has been named chair of Archeus’ advisory board, while Bruce D. Berndt has been appointed as a member of the company’s board of directors.
“These appointments strengthen critical areas of our organization as we advance multiple clinical trials and progress our broader pipeline of novel radiopharmaceutical therapies across a range of cancer indications,” said Evan Sengbusch, PhD, the company’s chief executive officer.
Archeus noted that in June 2025, it received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for its lead candidate ARC-706 for use with certain validated immunotherapies, as well as its companion diagnostics ARC-166 and ART-101 for imaging and treating prostate cancer.
